1. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials;Temel;Lancet Oncol,2016
2. Enobosarm, a selective androgen receptor modulator (SARM), increases lean bodymass (LBM) in advanced NSCLC patients; updated results of two pivotal, international phase 3 trials;Crawford;Support Care Cancer,2014
3. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA);Blum;Ann Oncol,2014
4. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review;Jafri;BMC Cancer,2013
5. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer;McMillan;Cancer Treat Rev,2013